Nicorette Mint Mundspray (Nicotine)

Nicotine, the active ingredient in Nicorette Mint Mundspray, is a nicotine replacement therapy presented as an oral spray for oromucosal use. The mint‑flavored spray conforms to EU standards and is designed to help adults who smoke manage withdrawal symptoms and cravings during smoking cessation attempts.

GNH USA supplies Nicorette Mint Mundspray as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide. The company ensures consistent quality, regulatory compliance, and reliable logistics for global distribution, and customers benefit from responsive technical support and traceability throughout the supply chain.

Nicotine delivered via Nicorette Mint Mundspray is used in nicotine replacement therapy to support smoking cessation. Smoking cessation: helps adults reduce withdrawal symptoms and cravings when quitting smoking. Tobacco dependence: provides a controlled nicotine dose to aid gradual reduction of nicotine intake. Relapse prevention: assists individuals who have recently quit to maintain abstinence from tobacco.

Common side effects are generally mild and related to the route of administration, while serious or rare reactions require medical attention. Common Side Effects: - Mouth irritation - Throat irritation - Hiccups - Nausea Serious or Rare Side Effects: - Allergic reaction (rash, swelling, itching) - Irregular heartbeat - High blood pressure - Persistent vomiting

Precautions should be considered before using Nicorette Mint Mundspray. Assess cardiovascular status: nicotine may increase heart rate and blood pressure. Avoid use in recent myocardial infarction: risk of cardiac events. Do not use during pregnancy: safety not established. Do not use while breastfeeding: nicotine can be transferred to infant. Follow prescribed frequency: exceed recommended use may worsen side effects. Store at room temperature: keep in original container, protect from moisture and heat.

Potential drug interactions may affect safety and efficacy. Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may increase risk of hypertension. - Bupropion: combined use can raise seizure risk. - CYP2A6 inhibitors (e.g., fluvoxamine): may alter nicotine metabolism leading to higher systemic levels. Moderate Interactions (Monitor Closely): - Alcohol: nicotine may enhance cardiovascular effects. - Caffeine: may increase jitteriness and palpitations. - Antihypertensive drugs: nicotine may reduce their efficacy.